Department of Urology, Erasmus MC, Rotterdam, The Netherlands.
Eur Urol. 2012 Feb;61(2):370-7. doi: 10.1016/j.eururo.2011.06.027. Epub 2011 Jun 24.
Active surveillance (AS) protocols for low-risk prostate cancer (PCa) generally include repeat prostate biopsies at predefined follow-up intervals.
To study the outcome of routinely obtained 1-yr repeat biopsies and factors predicting reclassification to higher risk, to contribute to risk stratification for men on AS.
DESIGN, SETTING, AND PARTICIPANTS: We analysed men with low-risk PCa (clinical stage ≤ T2, prostate-specific antigen (PSA) ≤ 10 ng/ml, PSA density <0.2 ng/ml per millilitre, one or two positive biopsy cores, and Gleason score ≤ 6) who had been included in a prospective AS protocol.
PSA was measured 3-monthly and the first volume-dependent repeat biopsy was scheduled 1 yr after diagnosis, independent of PSA doubling time (PSA-DT). Reclassification to higher risk disease on repeat biopsy was defined as Gleason score ≥ 7 or ≥ 3 positive cores.
We analysed whether baseline patient characteristics and PSA-DT were associated with reclassification to more aggressive PCa on repeat biopsy.
A first repeat biopsy was taken in 757 patients after median follow-up of 1.03 yr. The results of repeat biopsies were favourable (no or low-risk PCa) in 594 patients (78.5%) and led to reclassification of risk in 163 (21.5%). Analysis showed that reclassification to higher risk was significantly influenced by the number of initial positive cores (two vs one) (odds ratio [OR]: 1.8; p=0.002) and higher PSA density (OR: 2.1; p=0.003). The outcome was not significantly influenced by age, clinical stage, total number of biopsy cores, or PSA. Adding PSA-DT at time of repeat biopsy to the model showed PSA-DT <3 yr to be significantly associated with reclassification to higher risk (OR: 1.7; p=0.015). Data on tumour involvement per biopsy core were not available.
Clinical features at baseline and during follow-up in our AS cohort are significantly associated with short-term reclassification to higher risk on repeat biopsy. These characteristics can potentially be used for risk stratification of men with PCa who are apparently at favourable risk.
低危前列腺癌(PCa)的主动监测(AS)方案通常包括在预设的随访间隔内重复进行前列腺活检。
研究常规获得的 1 年重复活检的结果和预测风险升高的因素,为 AS 男性的风险分层提供依据。
设计、地点和参与者:我们分析了符合低危 PCa 标准的男性(临床分期≤T2、前列腺特异性抗原(PSA)≤10ng/ml、PSA 密度<0.2ng/ml/ml、1 或 2 个阳性活检核心、Gleason 评分≤6),这些男性被纳入了一项前瞻性 AS 方案。
PSA 每 3 个月测量一次,首次基于体积的重复活检在诊断后 1 年进行,与 PSA 倍增时间(PSA-DT)无关。重复活检中 Gleason 评分≥7 或≥3 个阳性核心被定义为高危疾病的再分类。
我们分析了基线患者特征和 PSA-DT 是否与重复活检中更具侵袭性 PCa 的再分类相关。
757 例患者在中位随访 1.03 年后进行了首次重复活检。594 例患者(78.5%)的重复活检结果为无或低危 PCa,163 例(21.5%)的结果导致风险重新分类。分析表明,再分类为高危风险显著受初始阳性核心数量(2 个 vs 1 个)(比值比[OR]:1.8;p=0.002)和较高的 PSA 密度(OR:2.1;p=0.003)的影响。结果不受年龄、临床分期、活检核心总数或 PSA 的显著影响。在重复活检时加入 PSA-DT 到模型中,PSA-DT<3 年与高危风险的再分类显著相关(OR:1.7;p=0.015)。关于每个活检核心的肿瘤受累情况的数据不可用。
我们的 AS 队列中的基线和随访期间的临床特征与短期重复活检时高危风险的再分类显著相关。这些特征可能有助于对低危 PCa 男性进行风险分层。